The popularity of Clustered Regularly Interspersed Short Palindromic Repeats (CRISPR) technology has enabled its extension to various biological domains, including probiotics. The uncertainty of therapeutic efficacy of traditional probiotics is being addressed with genetic engineering of bacteria with programmable gene cassettes. This has widened the applications of probiotics to anti-microbial purposes and the production of therapeutic peptide molecules. Despite being applicable to a vast range of organisms, CRISPR technology does face challenges from native bacterial members that differ in DNA repair pathways, in-vitro culture conditions and mechanisms for foreign genetic material take-up or degradation.
SciTech Patent Art reviews this technology in its report on “CRISPR technology for Next Generation Probiotics”. The report includes the following sections:
- A brief history of CRISPR technology, and the role of Dupont Nutrition and Biosciences in its evolution.
- Commercial utility of CRISPR in areas such as food and agriculture.
- How biotech firms are using CRISPR technology for producing therapeutic probiotics.
- Interesting patents from active players.